Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

NCT00689000 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome
Multiple Myeloma

Interventions

DRUG: CHR-2797 (tosedostat): Aminopeptidase inhibitor

Sponsor

Chroma Therapeutics